A number of studies have attempted to identify further PGVs associated with CBC risks, including previous WECARE (for Women’s Environment, Cancer and Radiation Epidemiology) Study publications that analyzed CHEK2*1100delC and variants in ATM and PALB2 [20,26,27,28]. This evidence concerns the gene CHEK2 and complete blood cell count.